Bayer Signs a Research and Development Collaboration with Arvinas for its PROTAC Technology

Shots:

• Arvinas to get ~$60M including upfront, equity investments, R&D funds and $685M milestones and royalties on sales of products. Bayer to get rights for the therapies developed in collaboration using Arvinas’s PROTAC Technology
• The focus of the collaboration is to develop therapies using Arvinas’ PROTAC protein degrader technology in cardiovascular, oncology, and gynecological disorders
• Arvinas’ PROTAC (Proteolysis-Targeting Chimera) is a protein degrader technology used for harnessing body’s own natural protein disposal system and further degrades disease-causing proteins into amino acids

Click here to read full press release/ article | Ref: Bayer | Image: Twitter